Current concepts and newer developments in cancer

International Journal of Pharmaceutical Sciences Review and Research

Volumn 3, Issue 2, 2010, Pages 85-89

  Thakur, Devendra Singh ^a   Kumar, Peeyush ^a   Kumar, Pramod ^a  

^a GURU GHASIDAS UNIVERSITY   (India)

Author keywords

Cancer; Fluorescent nanoparticles; Nanotechnology; Sonophoresis

Indexed keywords

APREPITANT; AURIMUNE; COLLOIDAL GOLD; CYCLODEXTRIN; CYCLOSERT; DOXORUBICIN; EMED; FENOFIBRATE; FLUOROURACIL; GOLD NANOPARTICLE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INGN 401; LIPOSOME; MEGESTROL ACETATE; NANOCRYSTAL; NANOSHELL; PACLITAXEL; QUANTUM DOT; RANTES; RAPAMYCIN; SGT 53; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TUMOR NECROSIS FACTOR; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VIVAGEL;

AUTOFLUORESCENCE; BIOCOMPATIBILITY; BREAST CANCER; CANCER CHEMOTHERAPY; CYTOTOXICITY; DIGESTIVE SYSTEM CANCER; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ECHOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NANOENCAPSULATION; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; PARTICLE SIZE; PASSIVE TRANSPORT; REVIEW; SOLID TUMOR; SONOPHORESIS; TUMOR MICROENVIRONMENT;

EID: 79952012677     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Panyam J, Labhasetwar V, Biodegradable nanoparticles for drug and gene delivery to cells and tissue, Adv Drug Deliv Rev, 55, 2003,329-347.
2. Birnbaum DT, Brannon-Peppas L, Microparticle drug delivery systems. In Drug delivery systems in cancer therapy, Ed. Brown DM, Humana Press, 2004, 117-135.
3. Harris JM, Chess RB, Effect of pegylation on pharmaceuticals, Nat Rev Drug Discov 2003, 2,214-221.
4. Desai N, Trieu V, Yao Z, Louie L, Ci S, et al., Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel, Clin Cancer Res, 2006, 12,1317-1324.
5. Fassas A, Anagnostopoulos A, The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia, Leuk Lymphoma, 2005, 46, 795-802.
6. Dragovich T, Mendelson D, Kurtin S, et al, A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer, Cancer Chemother Pharmacol, 2006,58,759-764.
7. Sapra P, Tyagi P, Allen TM, Ligand-targeted liposomes for cancer treatment, Curr Drug Deliv, 2005,2,369-381.
8. White SC, Lorigan P, Margison GP, et al., Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer, Br J Cancer, 2006, 95, 822-828.
9. Rosenthal DI, Yom SS, Liu L, et al. A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer, Invest New Drugs, 2002, 20, 343-349.
10. Harrington KJ, Lewanski CR, Northcote AD, et al., Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable headand neck cancer, Ann Oncol, 2001, 12, 493-496.
11. Ciuleanu T, Diculescu M, Hoepffner NM, et al. A randomised phase II study of OSI-7904Lversus 5- fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers, Invest New Drugs, 2007,25,385-390.
12. Clamp AR, Schöffski P, Valle JW, et al., A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer, Cancer Chemother Pharmacol, 2007, 23,[Epub ahead of print] PMID:17520255.
13. Paciotti GF, Myer L, Weinreich D, et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery, Drug Deliv, 2004, 11, 169-183.
14. Hainfeld JF, Slatkin DN, Smilowitz HM, The use of gold nanoparticles to enhance radiotherapy in mice, Phys Med Biol, 2004,49,N309-N315.
15. Chen J, Saeki F, Wiley BJ, et al. Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents, Nano Lett, 2005,5, 473-477.
16. Michel SC, Keller TM, Frohlich JM, et al., Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement, Radiology, 2002, 225, 527-536.
17. Hirsch LR, Stafford RJ, Bankson JA, et al., Nanoshell- mediated near-infrared thermal therapy of tumors under magnetic resonance guidance, Proc Natl Acad Sci USA, 2003,100,13549-13554.
18. Michel SC, Keller TM, Frohlich JM, et al. Preoperative breast cancer staging: MR imaging of the axilla with ultra small superparamagnetic iron oxide enhancement, Radiology, 2002,225,527-536
19. Vyas TK, Shah L, Amiji MM, Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites, Expert Opin. Drug Deliv, 2006, 3(5), 613-628.
20. Wan L, Pooyan S, Hu P, Leibowitz MJ, Stein S, Sinko PJ, Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophagetargeted peg-fmlf (n-formyl-methionyl-leucylphenylalanine) nanocarriers for improving HIV drug delivery, Pharm. Res,2007, 24(11), 2110-2119.
21. Diasio RB, Harris BE, Clinical pharmacology of 5- fluorouracil, Clin Pharmacokinet, 1989, 16, 215-237.
22. Yuasa H, Gu J, Hayashi Y, Watanabe J. First-pass metabolism of 5-fluorouracil in rats, J Pharm Pharmacol, 1998, 50, 1019-1025.
23. Gómez et al., Laser Treatments on Skin Enhancing and Controlling Transdermal Delivery of 5- Fluorouracil, Lasers in Surgery and Medicine, 2008, 40, 6-12.